Intravitreal bevacizumab (Avastin®) for diabetic retinopathy at 24-months: The 2008 Juan Verdaguer-planas lecture
| Autor: | Arevalo J.F., Sanchez J.G., Lasave A.F., Wu L., Maia M., Bonafonte S., Brito M., Alezzandrini A.A., Restrepo N., Berrocal M.H., Saravia M., Farah M.E., Fromow-Guerra J., Morales-Canton V., Espinoza J.V., Aggio F.B., Quiroz-Mercado H., Guerrero-Naranjo J.L., Rodriguez F.J., Infante R., Medina D., Cruz-Villegas V., Graue-Wiechers F., Lozano-Rechy D., Robledo V., Rodriguez-Loaiza J.L., Roca J.A., Reategui G., Saravia M.J., Martinez-Cartier M., Avila M., Cardillo J., Costa R.A., Verdaguer J., Carpentier C., Verdaguer J.I., Filsecker D.L., Sepúlveda G., Sanchez F., Marini C., Garcia B., Pan-American Collaborative Retina Study Group (PACORES) |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Male
optical coherence endocrine system diseases genetic structures Tractional retinal detachment Diabetic macular edema Diabetic retinopathy Proliferative diabetic retinopathy Treatment outcome Evaluation Middle aged Tomography Cell proliferation Priority journal Intravitreal injections Bevacizumab Retrospective study Macular thickness Panretinal photocoagulation Female Retina macula edema Human Monoclonal antibody Adult Retina detachment Visual acuity Angiogenesis inhibitors monoclonal Angiogenesis inhibitor Follow-up studies Article Antibodies Time Animals Humans Disease severity Aged Macular edema Optical coherence tomography Animal Time factors Diffuse diabetic macular edema Follow up Laser coagulation eye diseases Drug effect Retrospective studies Intravitreal drug administration sense organs Vascular endothelial growth factor Intravitreal bevacizumab |
| Zdroj: | Repositorio EdocUR-U. Rosario Universidad del Rosario instacron:Universidad del Rosario |
| Popis: | Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab (IVB) on DR including DME and PDR at 24 months of follow up. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse diabetic macular edema. Therefore, in the future this new therapy could replace or complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to pan-retina photocoagulation so that more selective therapy may be applied. In addition, we report a series of patients in which tractional retinal detachment developed or progressed after adjuvant preoperative IVB in severe PDR. © 2010 Bentham Science Publishers Ltd. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|